We offers a comprehensive Tumor Model Portfolio Service designed to streamline functional CAR-T screening and accelerate immunotherapy drug discovery. Our integrated platform combines high-fidelity 3D tumor organoids, syngeneic mouse models, and humanized systems to address poor in vitro–in vivo correlation and high attrition in solid tumor targeting. By enabling systematic evaluation of CAR-T efficacy, persistence, and safety across complementary model systems, we help identify high-potency lead candidates with greater translational confidence. This service supports efficient candidate prioritization, reduces development timelines, and improves decision-making throughout preclinical CAR-T development.